AlphAIAlphAI — Financial news for AI agents
investing.comNOV 31 min read$NBIX

Cantor Fitzgerald reiterates Neurocrine Bio stock rating on revenue growth

Cantor Fitzgerald maintained an Overweight rating and $215 price target on Neurocrine Biosciences (NASDAQ:NBIX) after its Q3 earnings beat expectations. The company reported $1.12B in revenue, up 38% YoY, with a 91% gross margin. Baird also reiterated an Outperform rating and $225 target, citing strong product performance and raised guidance for Ingrezza.

Original reporting
investing.com
Published Nov 3, 2026, 2:02 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 2:25 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefEarnings
Primary signal
$NBIX
Bullish
high confidence
Mentioned
$NBIX
Relevance
8/10
AlphAI data visualization · based on investing.com
Decision brief

The 30-second read

$NBIXBullishMed
01

Why it matters

The earnings beat and analyst rating upgrade provide a fresh catalyst that could drive short‑term buying pressure.

02

Market read

First report of NBIX's Q3 results and analyst upgrades, offering a clear trading catalyst.

03

What to watch

Potential regulatory or reimbursement risks for Ingrezza and Vykat are not addressed.

Relevance 8/10Novelty 8/10Timing: post‑market today

Background

Neurocrine Biosciences (NBIX) posted its Q3 2026 earnings, surpassing $1 B in quarterly revenue for the first time and beating consensus estimates.

Company-level read

Ticker impact

$NBIXBullishHigh confidence
Context

Cantor Fitzgerald reiterated Overweight and set a $215 price target after Neurocrine Biosciences reported Q3 revenue of $1.12 B and EPS of $3.29, beating estimates.

Expected impact

likely upward pressure as the market prices in the higher target and earnings beat

Evidence & confidence

The fresh earnings beat and upgraded rating provide a concrete catalyst for buying interest.

Market effects

Sector

Strong biotech earnings may lift peer valuations in the neuro‑degenerative drug space.

Regional

U.S. biotech sector gains modestly on the news.

Global

Limited to investors focused on U.S. biotech equities.

Counterpoint

What could challenge this read

If the revenue growth is not sustainable, the stock could face a pull‑back despite the upgrade.

Key entities

  • analyst
    Cantor Fitzgerald

    Reiterated Overweight rating and set $215 price target.

  • analyst
    Baird

    Maintained Outperform rating with $225 price target.

Read at source← All news

StoryNeurocrine Biosciences posts record Q3 2026 revenue and raises Ingrezza guidance

Also covered by

6 outlets

Related articles

NOV 3
$NBIXHighAI 8/10

NBIX Stock Jumps As Earnings Smash Estimates And Pipeline Expands

Neurocrine Biosciences Inc. (NBIX) stock rose 14.3% after strong Q3 earnings, with revenue of $1.12B (up from $794.9M YoY) and adjusted EPS of $3.29 (up from $2.17). The company also reported positive clinical data and expanded its pipeline, including a new Phase 2 trial for Alzheimer's treatment. Management raised FY26 revenue guidance to $2.9B–$2.925B, below consensus of $3.9B.

timothysykes.com2 min
NOV 3
$NBIXHighAI 9/10

Why is Neurocrine Biosciences stock surging today?

Neurocrine Biosciences (NBIX) stock rose 15.1% after reporting Q3 adjusted earnings of $3.29 per share, beating estimates by 72%, and revenue of $1.12 billion, up 41% YoY. The company surpassed $1 billion in net product sales for the first time, driven by its top products. Analysts raised price targets, with Baird setting a $225 target. Management increased 2026 INGREZZA sales guidance to $2.9-$2.925 billion.

investing.com2 min
NOV 3
$SIBNHigh

Healthcare Stocks Move Higher: SIBN Rallies 18%, NBIX Gains 16%, RMTI Climbs 16%, PTCT Up 13%

Healthcare stocks rose due to earnings reports and corporate actions. SI-BONE (SIBN) reported Q3 revenue of $55.7M, a 14.5% increase, and reaffirmed its full-year outlook. Neurocrine Biosciences (NBIX) reported Q3 revenue of $1.122B, up 41.1%. Rockwell Medical (RMTI) agreed to acquire Vantive's hemodialysis assets. PTC Therapeutics (PTCT) authorized a $500M share repurchase program.

rttnews.com2 min